Search Results

Genetown

Variantyx Secures $36M Investment As Testing Demand And Market Share Continues To Increase

Variantyx, a leader in molecular diagnostics, announced that it has secured an additional $36 million in funding from its portfolio of investors which includes Peregrine Ventures, Pitango HealthTech, New Era Capital Partners and Bosch Ventures.

April 26, 2024

·

2 min read

Genetown

Expanded STR Detection Capability Enables Variantyx to Diagnose Additional Genetic Disorders

Variantyx, a leader in genomic precision medicine, announced that the set of short tandem repeat expansions detected by its Genomic Unity® line of whole genome-based tests has been expanded.

November 30, 2023

·

2 min read

Genetown

Variantyx Expands Its Reproductive Health Offerings with Launch of a Direct Replacement for Chromosomal Microarray Analysis

Variantyx announced the launch of its IriSight™ CNV Analysis - a whole genome-based test for the detection of chromosomal abnormalities that correlate with clinical symptoms manifested in a fetus or a pregnancy, that may result in a genetic disorder or pregnancy loss.

November 10, 2023

·

1 min read

Genetown

Technology-Driven Precision Medicine Company Variantyx Secures $41.5M in Funding

Variantyx, a technology-driven precision medicine company providing advanced genomic testing for the rare genetic disorders, reproductive health, and precision oncology markets, announced they have secured $41.5M in funding.

February 14, 2022

·

2 min read

Genetown

Variantyx Surpasses 2,500 Genomes Analyzed, Highlights the Value of Its WGS-Based Testing Methodology

Clinicians at Variantyx, a leader in high complexity hereditary disease testing, recently completed analysis of their 2,500th patient genome

January 12, 2021

·

3 min read

Genetown

Variantyx Features Its Whole Genome Sequencing (WGS)-Based Epilepsy Test at American Epilepsy Society Annual Meeting

Variantyx announced today that it will be presenting its Genomic Unity® Epilepsy Analysis testing program at the American Epilepsy Society (AES) annual meeting December 7-9 in Baltimore, Maryland.

December 6, 2019

·

1 min read

Genetown

Variantyx Launches Its Whole Genome Sequencing (WGS)-Based In-Silico Panel Program at National Society of Genetic Counselors Annual Conference

Variantyx today announced the launch of its in-silico panel program which is an extension of its Genomic Unity™ whole genome sequencing (WGS)-based testing service. Available to clinicians since 2017, Genomic Unity™ has been instrumental in resolving many complex patient cases

November 5, 2019

·

1 min read

Genetown

Variantyx Launches Variantyx Unity, The All-In-One Genomic Diagnostic Test

September 13, 2017

·

1 min read

Genetown

Variantyx Launches Its RareDx Program, Providing Clinical Whole Genome Testing to Enrolled Patients

The program is additionally expected to raise awareness of the struggles that rare disease patients face in obtaining a diagnosis and the role that clinical whole genome testing can play in ending years’ long diagnostic odysseys.

February 28, 2019

·

1 min read

Genetown

Variantyx And FDNA Announce Integration Of Their Applications To Facilitate Rare Disease Diagnosis

August 30, 2017

·

2 min read